Mark J. Ratain to National Cancer Institute (U.S.)
This is a "connection" page, showing publications Mark J. Ratain has written about National Cancer Institute (U.S.).
Connection Strength
0.640
-
Do patent applications and Cooperative Research and Development Agreements between the National Cancer Institute and industry serve the public interest? Nat Biotechnol. 2023 Nov; 41(11):1517-1519.
Score: 0.234
-
Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clin Cancer Res. 2015 Nov 15; 21(22):5057-63.
Score: 0.135
-
Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clin Cancer Res. 2014 Aug 15; 20(16):4210-7.
Score: 0.124
-
The investigational drug steering committee. Clin Adv Hematol Oncol. 2007 Oct; 5(10):779-80.
Score: 0.077
-
Opportunities and challenges in the development of experimental drug combinations for cancer. J Natl Cancer Inst. 2011 Aug 17; 103(16):1222-6.
Score: 0.025
-
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res. 2010 Mar 15; 16(6):1764-9.
Score: 0.023
-
Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res. 2010 Mar 15; 16(6):1745-55.
Score: 0.023